A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Exclusion Criteria

• •1. Accompanied by untreated or active central nervous system (CNS) metastases. Subjects with a history or current history of meningeal metastasis.
• •2. Systemic antitumor therapy was received 4 weeks before the start of the study.
• •3. Palliative radiotherapy was completed within 14 days before the first dose.
• •5. Subjects with known or suspected interstitial pneumonia.
• •6. Moderate or severe ascites with clinical symptoms; Uncontrolled or moderate or higher pleural effusion or pericardial effusion.
• •7. Have poorly controlled or severe cardiovascular disease.
• •8. Subjects with active hepatitis B or active hepatitis C.
• •9. A history of immunodeficiency, including a positive HIV test, other acquired or congenital immunodeficiency disorders, or a history of organ transplantation.
• •10. The presence of uncontrolled mental illness and other conditions known to affect the completion of the study process, such as alcohol, drug or substance abuse, and criminal detention.
• •11. Any other factors that may increase the risk of participating in the study, interfere with the study results, or make participation in the study inappropriate as judged by investigators.